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Brain tumours are the commonest childhood neoplasm, with a world-
wide incidence of 29.9– 47.1/million [1]. Childhood brain tumours 
carry substantial morbidity/mortality and are the largest cause of 
paediatric cancer deaths [2]. Historically, classification was largely 
based on histological features. In recent years, the expansion of high- 
resolution genomic, epigenetic and transcriptomic profiling has led 
to improved molecular understanding and categorisation, as well as 
targeted therapies [3]. Consequently, the 2016 WHO classification 
incorporated molecular features in some brain tumour entities [4]. 
According to this classification, astroblastomas are extremely rare, 
not formally graded, and listed under ‘other gliomas’. Astroblastomas 
are generally treated by surgery alone but can display intermediate 
behaviour with high recurrence rates and unpredictable behaviour 
[5,6]. Controversy exists as to whether astroblastomas are a truly dis-
tinct entity as they have histological features in common with both 
astrocytomas and ependymomas [7- 9]. Diagnosing astroblastomas 
is therefore challenging and misclassification can alter subsequent 
management [8]. The present case demonstrates how recent molec-
ular advances identified two gene fusions for this patient, confirmed 
a more precise tumour diagnosis and guided subsequent manage-
ment decisions. The findings here have general importance to other 
rare paediatric brain tumour entities.
A 13- year- old girl presented with a 2- week history of morning 
headaches, vomiting and visual loss. There was no prior history of 
note. On examination, bilateral papilloedema and central visual field 
loss were confirmed. MRI head showed a 6.0 × 5.5 × 4.2 cm mixed 
solid- cystic lesion centred in the right cingulate gyrus/corpus callo-
sum (Figure 1A– C) with associated hydrocephalus, treated with intra-
venous dexamethasone. No other lesions were identified, and spinal 
MRI was clear. Serum AFP/HCG tumour markers were negative. 
The patient underwent a stealth- guided craniotomy with complete 
macroscopic resection of the frontal tumour. The patient recovered 
well postoperatively with no complications. Postoperative MRI head 
scan with contrast showed no residual tumour (Figure 1D).
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Histological examination demonstrated a cellular neuroepithelial 
tumour with a perivascular growth pattern forming vague pseudo- 
rosettes (Figure 1E). In some areas, there was marked stromal and 
vascular collagenisation. There was no mitotic activity and no mi-
crovascular proliferation. The tumour had a generally noninfiltrative 
border with surrounding brain tissue. There were occasional eosino-
philic granular bodies and no Rosenthal fibres or ganglion cell com-
ponents. The tumour had focal strong staining for GFAP and only 
weak staining for synaptophysin (Figure 1F/G). There was only very 
sparse mitotic activity and a low Ki67 proliferation index (2.5%), as 
evidenced by MIB1 staining (Figure 1H). The histological and immu-
nohistochemical features were most consistent with a diagnosis of 
astroblastoma.
Methylation profiling of the tumour [10] using the Illumina EPIC 
array platform and analysed using the DKFZ Heidelberg classifier, 
gave a very low calibration score of <0.9 (specifically 0.0475 at the 
time of reporting using classifier version MNPv11b4, and 0.0764 
with the most recent version MNPv11b6). These scores were too 
low for reliable classification despite excellent probe hybridisation 
(only 0.09% of probes failed), suggesting that the tumour was un-
classifiable compared with currently recognised tumour entities. 
This was confirmed by comparing the tumour's methylation pro-
file with other CNS tumour entities (Figure 2A). Regarding ge-
nomic alterations, inter- chromosomal gene fusions involving the 
MN1 gene (MN1- BEND2 and MN1- CXXC5) have previously been 
reported in CNS high- grade neuroepithelial tumours (HGNETs) 
[11], and recently it has been reported that a proportion of these 
CNS- HGNET- MN1 tumours exhibited histological features com-
patible with astroblastomas [12]. Following informed consent, 
whole- genome sequencing (WGS) was performed under the 
100,000 Genomes Project [13] and under appropriate ethical ap-
provals. WGS deployed Version 1.8 of the analysis pipeline devel-
oped by Genomics England (Supplementary Results). This analysis 
revealed a quiescent genome harbouring 6,218 substitutions and 
1,214 small insertions/deletions. Of these, just 28 genic nonsyn-
onymous variants were identified, all likely benign passengers. In 
addition, 721 structural variants were reported, almost exclusively 
concentrated via complex intra- and inter- chromosomal rearrange-
ments between chromosomes 17, 19 and 22. Loss of chromosome 
9 was the only additional chromosomal imbalance. Of note, the X 
chromosome remained intact in this patient, which is often dis-
rupted in CNS- HGNET- MN1 tumours (Supplementary Results, 
Figure S1). The structural variant data included a somatically ac-
quired paracentric inversion on the chromosome 22 long arm. The 
intragenic breakpoints were located in intron 1 of the MN1 gene 
and intron 2 of the GTSE1 gene (Figure 2B). Fluorescent sequenc-
ing analysis confirmed the presence of the novel MN1- GTSE1 gene 
fusion. The predicted chimeric protein retained the uninterrupted 
coding sequence of MN1 exon 1, apposed in frame, with exons 
3– 12 of GTSE1. This pattern of rearrangement closely resembled 
the genomic features of the previously reported MN1 gene fu-
sions involving BEND2 and CXXC5. Similar disruptive MN1 variants 
were absent from 1,903 other 100,000 Genomes Project cancer 
cases, mainly derived from breast, ovary, endometrium, colon and 
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F I G U R E  1  Representative neuroradiological imaging (A– D) and neuropathology (E– H) of the tumour. Neuroradiology (A– D): (A) Axial 
T2W; (B) Axial postgadolinium 3D T1; and (C) Axial FLAIR sequences showed a well- circumscribed solid- cystic tumour in the right cingulate 
gyrus and corpus callosum, which crossed the midline and extended into the right lateral ventricle. The lesion had a local mass effect 
causing a large area of surrounding vasogenic oedema and secondary hydrocephalus. The solid components enhanced and contain some 
areas of low T2W signal intensity from calcification. The large anterior tumoural cyst was of high signal on FLAIR because of proteinaceous 
content. To assess the vascularity of the tumour preoperatively, digital subtraction angiography was also performed which demonstrated 
displacement of the anterior cerebral arteries to the left side, consistent with mass effect secondary to tumour, but minimal tumour ‘blush’ 
following contrast phasing through the brain centrally. Consequently, no embolisation was performed. (D) Early postoperative axial T2W 
showing complete resection of the tumour. Neuropathology (E– H): all images taken at 10× magnification. (E) Representative haematoxylin 
and eosin (H&E) staining of the tumour, showing perivascular pseudo- rosette formation (black arrow) and stromal collagenisation; (F) GFAP 
staining showing strong and diffuse staining in glial cells surrounding blood vessels. Cells with neurocytic differentiation are negative; (G) 
Synaptophysin staining revealing positivity in cells with neurocytic or neuronal differentiation; (H) Sparse MIB1 staining, confirming a low 
Ki67 proliferation index (2.5%)
(A) (B) (C) (D)
(H)(G)(F)(E)
kidney. These observations support the functional validity of the 
novel MN1- GTSE1 variant reported here. Interestingly, in this tu-
mour, an EWSR1 (Ewing- Sarcoma- Breakpoint- Region- 1) and PATZ1 
(POZ/BTB- And- AT- Hook- Containing- Zinc- Finger- 1) (EWSR- PATZ1) 
gene fusion was also detected. This similarly involved inversion of 
chromosome 22 and a recent study suggests it may be consistent 
with a new glioneuronal tumour entity [14]. As a result of this un-
expected additional finding, we explored this in more detail. Three 
F I G U R E  2  Molecular interrogation of the tumour – MN1 fusion. (A) t- SNE (t- Distributed Stochastic Neighbour Embedding) plot based on 
the top 10,000 most variably methylated probes. Parameters used: perplexity = 20, theta = 0.5, dims = 2. The index case was compared with 
DNA methylation profiles available from DKFZ (Heidelberg Molecular Neuropathology platform, https://www.molec ularn europ athol ogy.
org/mnp) and those held locally [24] with a confirmed molecular classification (calibrated score using MNPv11b6 >0.9). Samples are coloured 
according to their methylation class: HGNET BCOR: CNS high- grade neuroepithelial tumour with BCOR alteration; HGNET MN1: CNS high- 
grade neuroepithelial tumour with MN1 alteration; EPN RELA: ependymoma, RELA fusion; LG GG: low- grade glioma, ganglioglioma; LG PA/
GG ST: low- grade glioma, hemispheric pilocytic astrocytoma and ganglioglioma; LG DNT: low- grade glioma, dysembryoplastic neuroepithelial 
tumour. The index case is in grey (highlighted by the black arrow), and does not cluster with any of the above entities. (B) Schematic of 
the genomic rearrangement resulting in a novel MN1- GTSE1 gene fusion. Whole- genome sequencing detected a somatically acquired 18 
megabase (Mb) paracentric inversion on the long arm of chromosome 22, between the cytogenetic bands 22q12.1 and 22q13.31 (top image). 
The genomic coordinates of the intragenic breakpoints (genome reference build 38) map to intron 1 of the MN1 gene (NCBI Entrez Gene 
transcript identifier NM_016426) and intron 2 of the GTSE1 gene (transcript NM_002430) (middle image). This inversion apposes exon 1 
of MN1 to exon 3 of GTSE1 in the same read direction, causing an MN1- GTSE1 gene fusion (lower image). Fluorescent sequencing analysis 
confirmed this fusion, which included nontemplate sequence ‘CTGGT.’ Upon splicing and transcription, this fusion is predicted to maintain 
the amino acid read frame and thus result in a novel MN1- GTSE1 chimeric protein. Key: block arrows represent exons; grey connecting lines 
represent introns; grey: untranslated regions; red: MN1 coding exons; blue: GTSE1 coding exons; Amino acid abbreviations: Ser, serine; Lys, 
lysine; Glu, glutamic acid; Asp, aspartic acid; Ile, isoleucine; Leu, leucine
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available glioma cases known to harbour PATZ1 fusions were 
added to the methylation profiling comparison. Intriguingly, our 
astroblastoma case, with both MN1 and PATZ1 fusions, remained 
distanced from the CNS- HGNET- MN1 tumours but now clustered 
with the three PATZ1 cases (Figure 3A). Further assessment of the 
EWSR1- PATZ1 fusion showed that the intragenic breakpoints were 
F I G U R E  3  Molecular interrogation of the tumour – PATZ1 fusion. (A) t- SNE plot based on the top 10,000 most variably methylated probes, 
as in Figure 2A, but with additional cases including three PATZ1- fusion gliomas. Samples are coloured according to their methylation class: 
CN: central neurocytoma; DLGNT: diffuse leptomeningeal glioneuronal tumour; DMG K27: diffuse midline glioma with H3 K27M mutation; 
EFT CIC: Ewings- like family tumour with CIC alteration; EPN RELA: ependymoma, RELA fusion; GBM RTKI: glioblastoma receptor tyrosine 
kinase I group; HGNET BCOR: CNS high- grade neuroepithelial tumour with BCOR alteration; HGNET MN1: CNS high- grade neuroepithelial 
tumour with MN1 alteration; LGG DNT: low- grade glioma, dysembryoplastic neuroepithelial tumour; LG GG: low- grade glioma, ganglioglioma; 
LGG MYB: low- grade glioma MYB/MYB1; LG PA/GG ST: low- grade glioma, hemispheric pilocytic astrocytoma and ganglioglioma; NB FOXR2: 
neuroblastoma FOXR2- altered; O IDH: IDH glioma, 1q/19q codeleted oligodendroglioma; PATZ1: PATZ1- fusion positive cases (identified by 
TruSight RNA fusion panel, Illumina). The index case is in grey (highlighted by the black arrow), and clusters with the PATZ1 cases (dark green). 
(B) Schematic of the genomic rearrangement resulting in an EWSR1- PATZ1 gene fusion. Whole- genome sequencing detected a somatically 
acquired 2.1 megabase (Mb) paracentric inversion on the long arm of chromosome 22, within the cytogenetic band 22q12.2 (top image). 
The genomic coordinates of the intragenic breakpoints (genome reference build 38) map to intron 9 of the EWSR1 gene (NCBI Entrez Gene 
transcript identifier NM_013986) and exon 1 of the PATZ1 gene (transcript NM_014323) (middle image). This inversion apposes exon 9 of 
EWSR1 to exon 1 of PATZ1 in the same read direction, causing an EWSR1- PATZ1 gene fusion (lower image). Breakpoint spanning reads in 
Integrative Genomics Viewer (IGV) evidence this fusion event (paired reads: 28; split reads: 30), mapping to EWSR1 intron 9 and PATZ1 exon 
1. This fusion is predicted to maintain the amino acid reading frame and thus result in a EWSR1- PATZ1 chimeric protein. Key: block arrows 
represent exons; grey connecting lines represent introns; grey: untranslated regions; blue: EWSR1 coding exons; red: PATZ1 coding exons; 
Amino acid abbreviations: Gly, glycine; Met, methionine; Pro, proline
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located in intron 9 of the EWSR1 gene and exon 1 of the PATZ1 
gene (Figure 3B). The position of the rearrangement breakpoints 
are consistent with those in a reported glioneuronal tumour with 
an EWSR1- PATZ1 gene fusion, placing the PATZ1 breakpoint at the 
same codon of exon 1, with RNA- sequencing data confirming ex-
pression of the chimeric transcript.[14] This report supports the 
validity of the equivalent EWSR1- PATZ1 variant reported here. 
Fusion genes involving MN1 and PATZ1 (MN1- PATZ1) have also very 
recently been described in a malignant paediatric brain tumour 
[15]. We carefully explored our data for evidence of rearrange-
ments (including translocations and tandem duplications) that 
could similarly adjoin MN1 and PATZ1 in functional orientation. We 
did not find evidence supporting this proposition. However, amidst 
the rearrangement complexity, we cannot exclude the presence of 
undetected cryptic events, as have been observed to generate on-
cogenic fusions in human cancer [16].
Astroblastomas are associated with high recurrence rates and an 
unpredictable biological course [5,6], with initial peri- tumoural oe-
dema, as was present in this case, associated with early recurrence 
[17]. Consequently, with the molecular confirmation of an astroblas-
toma, the multi- disciplinary- team outcome was to undertake MRI 
surveillance at 3- monthly intervals for the first year of follow- up, 
instead of the more conservative 6- monthly scan schedule gener-
ally associated with low- grade tumours. At subsequent review, the 
bilateral papilloedema had resolved and there were no abnormal 
neurological findings on examination. All subsequent MRI scans have 
showed no tumour recurrence over a 36- month postoperative pe-
riod, with the frequency of scans being reduced over time (3- monthly 
first year; 4- monthly second year; 6- monthly in the third year).
Here, we describe a patient with a rare astroblastoma, 
where additional molecular study assisted patient management. 
Neuropathologically, the differential diagnoses were an astroblas-
toma or glioneuronal tumour. Precise diagnosis is critical as it influ-
ences postoperative management decisions. Here, the molecular 
confirmation of the novel MN1- GTSE1 gene fusion, diagnostic of 
astroblastoma, supported the team in recommending 3- monthly fol-
low- up, rather than the standard 6- monthly approach which would 
be more typical for a glioneuronal tumour.
Astroblastomas typically arise at supratentorial sites, although 
occasional infratentorial cases occur [18,19]. On MRI, they appear as 
well- demarcated solid- cystic lesions and typically extend from cor-
tex to periventricular regions [20]. Commonly, calcification is seen 
in addition to a ‘bubbly’ appearance, arising from signal voids due to 
tumour angioarchitecture [21,22]. The lesions are typically hyper-
intense to white matter (FLAIR/T2- weighted sequences) and show 
heterogeneous enhancement with rim enhancement on contrast- 
enhanced CT and T1- weighted MRI [9,22]. Our case showed many of 
these neuroradiological features (Figure 1A– C).
Histologically, astroblastomas are characterised by peri-
vascular hyalinisation and pseudo- rosettes [8]. While these 
pseudo- rosettes contribute to the diagnostic criteria, they may 
be completely undetectable [12]. A lack of fibrillary background, 
hyalinised vessels, and a compressive, rather than infiltrative, 
margin is also commonly observed [20]. Immunohistochemically, 
astroblastomas are typically positive for GFAP, vimentin and S- 100 
protein [20], although there is variability in staining [8]. Although 
there is currently no formal grading for astroblastomas (based on 
the 2016 WHO classification), a putative informal system has been 
suggested, with ‘high- grade’ tumours showing high cellularity, an-
aplastic nuclear features, vascular proliferation, high mitotic rates 
and necrosis [12], which may be considered for inclusion in future 
classifications.
Molecular data for astroblastomas are limited [23]. This is 
consistent with methylation profiling being uninformative in this 
case, despite its overall utility for paediatric brain tumours [24]. 
Interestingly, despite re- running the classifier again in 2020, the 
calibration score of 0.0764 was again too low for reliable classi-
fication. DNA methylation studies on CNS high- grade neuroep-
ithelial tumours (CNS- HGNETs) revealed a distinct methylation 
cluster of recurrent meningioma- 1 (MN1) gene rearrangements 
on chromosome 22q. The majority of astroblastomas matched 
the CNS- HGNET- MN1 tumour cluster (not seen here; Figure 2A) 
and approximately 40% of the CNS- HGNETs with MN1 alteration 
showed histological features of astroblastomas. Furthermore, RNA 
sequencing revealed two inter- chromosomal gene fusions involv-
ing the MN1 gene (MN1- BEND2 and MN1- CXXC5) [11,12]. Thus, it 
is plausible that the genetic basis of astroblastomas may involve 
MN1 rearrangement with fusion partner genes, such as BEND2, 
CXXC5 and other unidentified genes [12]. This is supported by an-
other studying showing MN1 alterations in four of eight tumours 
diagnosed histologically as astroblastomas [25]. In our patient, we 
confirmed a novel MN1- GTSE1 gene fusion, which to our knowl-
edge, is the first such description in an astroblastoma. Interestingly, 
we also observed an EWSR1- PATZ1 fusion generated through the 
rearrangement complexity emanating on chromosome 22, which 
has been described in glioneuronal tumours and sarcoma [14,26]. 
Whilst it is unusual to find two oncogenic gene fusions in the same 
tumour, this is not unprecedented [27]. It may represent the devel-
opment of two parallel clones with uniform (i.e. nonbiphasic) histol-
ogy or a double hit within the same clone.
From a diagnostic perspective, our observation of two fusions 
in this case are intriguing, as without WGS neither fusion would 
have been detected and our retrospective, integrated interpreta-
tion, requiring up- to- date molecular subtyping for context, was crit-
ical, despite the astroblastoma histology. We believe that this case 
is unlikely to represent a typical CNS- HGNET- MN1 tumour, due to 
the dissimilarity in methylation profile compared with reference 
HGNET- MN1 cohorts, the similarity with PATZ1- fusion cases and the 
intact X chromosome seen here (frequently disrupted in HGNET- 
MN1 tumours). Such questions will be answered more definitively in 
time, as our diagnostic services move away from single- gene testing 
to WGS and other NGS sequencing technologies, alongside methyl-
ation profiling, for CNS tumours. Single- gene testing for MN1 (e.g. 
break- apart FISH or PCR) is not available via our standard clinical 
practices, despite MN1 FISH data being described in the literature. 
However, in England, all children with CNS tumours are now eligible 
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for commissioned WGS via Genomics England. We would therefore 
expect to identify gene fusions and their variants via this route.
In conclusion, astroblastomas are rare brain tumours with an un-
predictable biological course and recurrence pattern, that present 
potential diagnostic challenges. Despite noninformative methyla-
tion studies, this case highlighted a novel MN1- GTSE1 gene fusion 
detected on WGS, in keeping with other studies of MN1 gene al-
terations in astroblastomas and supported increased frequency of 
standard MRI surveillance. The additional detection of a second 
EWSR1- PATZ1 fusion highlights the complexity of such cases. Recent 
expansion of high- resolution genomic and other molecular profiling 
for paediatric brain tumours is likely to continue to lead to improved 
diagnostic and prognostic techniques, with consequent positive im-
pacts on patient management.
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